search
Back to results

Antibiotic Use & Open Fracture of the Lower Extremity

Primary Purpose

Lower Extremity Fracture

Status
Suspended
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Cephalosporin 1St Generation
Aminoglycosides
Sponsored by
Methodist Health System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lower Extremity Fracture focused on measuring Gustilo

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female patients ≥ 18 years of age
  • All patients with open grade II or grade III lower extremity open fractures according to the Gustilo Classification of open fracture.

Exclusion Criteria:

  • Any significant injuries in addition to the lower extremity fracture as determined by the PI that may confound the data.
  • Inability to give informed consent or comply with data acquisition (Part 3).
  • Pregnant or breast feeding patients due to the potential risks to the mother and/or fetus.
  • Prisoners
  • Previous bone malignancy
  • Bowel or enteric injury at index admission
  • TBI of AIS ≥ 5

Sites / Locations

  • Methodist Health System

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

cephalosporin

cephalosporin and aminoglycoside

Arm Description

cephalosporin

the combination of cephalosporin and aminoglycoside.

Outcomes

Primary Outcome Measures

Aminoglycoside Usage
The necessity of aminoglycoside usage for patients with open lower extremity fractures.

Secondary Outcome Measures

Demographics
age, sex, ethnicity
comorbidities
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
Total hospital length of stay - HLOS
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
deep space infection (DSI)
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
grade of fracture
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
surgical site infection (SSI)
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures

Full Information

First Posted
August 12, 2019
Last Updated
March 1, 2022
Sponsor
Methodist Health System
search

1. Study Identification

Unique Protocol Identification Number
NCT05267977
Brief Title
Antibiotic Use & Open Fracture of the Lower Extremity
Official Title
Antibiotic Use & Open Fracture of the Lower Extremity
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Suspended
Study Start Date
August 2016 (Actual)
Primary Completion Date
August 2023 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Methodist Health System

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
It is important to recognize the potential for renal injury and be cognizant of this during the management of complex trauma patients. The primary aim of this study is to investigate the necessity of aminoglycoside usage for patients with open lower extremity fractures. Hypothesis: adding aminoglycoside on top of cephalosporin in treating lower extremity fracture will make no significant difference in term of clinical outcomes when compared to cephalosporin alone.
Detailed Description
The trauma patient is particularly susceptible to renal injury due to factors such as renal hypoperfusion in the acute setting, the concomitant administration of necessary intravenous contrast agents for diagnostic, and sometimes additionally therapeutic imaging (3). This is additionally complicated by the presentation of trauma patients with pre-existing renal disease. This study will assess whether prophylactic antibiotics <72hrs have similar outcomes as ≥ 72 hrs of antibiotics, whether type of antibiotics impacts outcomes in patients in either group, help determine the incidence of infection in Gustilo Type III lower extremity fracture when treated either with a single agent (cephalosporin) or dual agent (cephalosporin + aminoglycoside) and the complication profile of patients with Gustilo Type III lower extremity fracture when treated either with a single agent (cephalosporin 1st generation) or dual agent (cephalosporin 1st generation + aminoglycoside).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lower Extremity Fracture
Keywords
Gustilo

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Phase: Part 1: Retrospective multi-center study. Part 2: Prospective multi-center study. Number of Sites: Methodist Health System and the associated center. Description of Intervention: Phase 1: No intervention. Phase 2: Patients will be randomized to receive either cephalosporin or the combination of cephalosporin and aminoglycoside. Study Duration: Phase 1: 3 years. Phase 2: 5 years. Subject Participation Duration: Phase 2: Patients will be enrolled in the study until discharge from the hospital. Study participation is strictly voluntary and patient can withdraw at any time.
Masking
Participant
Allocation
Randomized
Enrollment
948 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
cephalosporin
Arm Type
Active Comparator
Arm Description
cephalosporin
Arm Title
cephalosporin and aminoglycoside
Arm Type
Active Comparator
Arm Description
the combination of cephalosporin and aminoglycoside.
Intervention Type
Drug
Intervention Name(s)
Cephalosporin 1St Generation
Intervention Type
Drug
Intervention Name(s)
Aminoglycosides
Primary Outcome Measure Information:
Title
Aminoglycoside Usage
Description
The necessity of aminoglycoside usage for patients with open lower extremity fractures.
Time Frame
Within 24 hours of admission
Secondary Outcome Measure Information:
Title
Demographics
Description
age, sex, ethnicity
Time Frame
Within 24 hours of admission
Title
comorbidities
Description
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
Time Frame
Within 24 hours of admission
Title
Total hospital length of stay - HLOS
Description
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
Time Frame
Within 24 hours of admission
Title
deep space infection (DSI)
Description
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
Time Frame
Within 24 hours of admission
Title
grade of fracture
Description
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
Time Frame
Within 24 hours of admission
Title
surgical site infection (SSI)
Description
in regards to necessity of aminoglycoside usage for patients with open lower extremity fractures
Time Frame
Within 24 hours of admission

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients ≥ 18 years of age All patients with open grade II or grade III lower extremity open fractures according to the Gustilo Classification of open fracture. Exclusion Criteria: Any significant injuries in addition to the lower extremity fracture as determined by the PI that may confound the data. Inability to give informed consent or comply with data acquisition (Part 3). Pregnant or breast feeding patients due to the potential risks to the mother and/or fetus. Prisoners Previous bone malignancy Bowel or enteric injury at index admission TBI of AIS ≥ 5
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael S. Truitt, MD
Organizational Affiliation
Methodist Dallas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Methodist Health System
City
Dallas
State/Province
Texas
ZIP/Postal Code
75203
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Antibiotic Use & Open Fracture of the Lower Extremity

We'll reach out to this number within 24 hrs